Skip to Content

Innoviva Inc INVA

Morningstar Rating
$17.20 −0.27 (1.55%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

INVA is trading at a 512% premium.
Price
$17.46
Fair Value
$37.92
Uncertainty
High
1-Star Price
$58.83
5-Star Price
$89.56
Economic Moat
Chfr
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if INVA is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$17.47
Day Range
$17.1917.43
52-Week Range
$12.2317.53
Bid/Ask
$17.17 / $17.20
Market Cap
$1.07 Bil
Volume/Avg
127,083 / 540,692

Key Statistics

Price/Earnings (Normalized)
10.76
Price/Sales
4.79
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield
4.04%

Company Profile

Innoviva Inc is a company with a portfolio of royalties and innovative healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Growth
Total Number of Employees
112

Competitors

Valuation

Metric
INVA
PFE
AZN
Price/Earnings (Normalized)
10.7620.9621.59
Price/Book Value
1.561.846.60
Price/Sales
4.793.085.23
Price/Cash Flow
8.9019.7724.68
Price/Earnings
INVA
PFE
AZN

Financial Strength

Metric
INVA
PFE
AZN
Quick Ratio
8.510.670.70
Current Ratio
10.421.050.89
Interest Coverage
9.81−0.265.32
Quick Ratio
INVA
PFE
AZN

Profitability

Metric
INVA
PFE
AZN
Return on Assets (Normalized)
15.69%3.77%59.78%
Return on Equity (Normalized)
29.88%8.51%157.53%
Return on Invested Capital (Normalized)
17.71%5.75%88.21%
Return on Assets
INVA
PFE
AZN
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Novo Nordisk A/S ADR
NVO
RtbngyzflKybhx$598.1 Bil
Vertex Pharmaceuticals Inc
VRTX
KrlnlptwMbwpcp$126.0 Bil
Regeneron Pharmaceuticals Inc
REGN
WmtrxqzmzNydvk$119.6 Bil
Moderna Inc
MRNA
MtvtmytyYjwv$47.5 Bil
Alnylam Pharmaceuticals Inc
ALNY
VcdxkyxxXvqxply$30.4 Bil
argenx SE ADR
ARGX
VbdthjjwcMwft$27.4 Bil
BioNTech SE ADR
BNTX
PqnqlfqSkgm$20.8 Bil
Biomarin Pharmaceutical Inc
BMRN
LsbzcjdyMsjlrlb$16.1 Bil
United Therapeutics Corp
UTHR
DgtxpdqbBzcm$14.7 Bil
Incyte Corp
INCY
TsdfbwsqDthppn$12.9 Bil

Sponsor Center